Skip to main content

Advertisement

Table 1 Summary statistics of patients in IMPRES RCT

From: Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension

Baseline therapy Add-on Therapy Size¶ Drop out§ Mean 6MWD improvement Mean age Prop male Mean STATUS Mean 6MWD baseline Mean PVR
ERA + PDE5i Placebo* 23 4 2.54 (16.25) 50.30 0.30 2.96 342.07 1157.0
ERA + PDE5i Imatinib 20 12 43.7 (14.27) 50.15 0.10 2.60 328.95 1282.1
ERA + Pr Placebo 8 2 7.81 (14.36) 37.00 0.25 2.38 381.56 1146.6
ERA + Pr Imatinib 10 5 48.3 (16.12) 47.20 0.00 2.80 331.60 1071.9
ERA + PDE5i + Pr Placebo 33 8 −8.27 (10.47) 47.03 0.18 2.73 355.79 1176.6
ERA + PDE5i + Pr Imatinib 27 15 33.37 (11.54) 47.74 0.19 2.85 360.70 1232.5
PDE5i + Pr Placebo 16 4 36.03 (10.53) 43.19 0.06 2.56 358.72 1193.9
PDE5i + Pr Imatinib 9 5 40 (14.59) 53.00 0.11 2.78 380.56 1050.8
  1. *ERA is any endothelin receptor antagonist, PDE5i is phosphodiesterase 5 inhibitor, and Pr is prostacyclins (oral, inhaled, intravenous or subcutaneous).
  2. ¶ Group size was number of patients taking 6MWD test at baseline and 24 weeks.
  3. § Dropout is number of patients dropping out of the study between baseline and 24 weeks. Dropout due to death, adverse events, consent withdrawal, protocol deviation, abnormal laboratory result, administrative error, or adverse reaction to study drug.